<scp>Yes‐associated protein 1</scp> mediates initial cell survival during lorlatinib treatment through <scp>AKT</scp> signaling in <scp>ROS1</scp> ‐rearranged lung cancer-Reference-Cited by-同舟云学术

Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1 ‐rearranged lung cancer

Published:2022-11-23 Issue:2 Volume:114 Page:546-560
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Yamazoe Masatoshi¹,Ozasa Hiroaki¹^ORCID,Tsuji Takahiro¹²^ORCID,Funazo Tomoko¹,Yoshida Hiroshi¹,Hashimoto Kentaro¹,Hosoya Kazutaka¹,Ogimoto Tatsuya¹,Ajimizu Hitomi¹,Yoshida Hironori¹,Itotani Ryo¹,Sakamori Yuichi¹,Kuninaga Kiyomitsu¹,Aoki Wataru³,Hirai Toyohiro¹

Affiliation:

1. Department of Respiratory Medicine, Graduate School of Medicine Kyoto University Kyoto Japan

2. Department of Anatomy and Molecular Cell Biology, Graduate School of Medicine Nagoya University Nagoya Japan

3. Division of Applied Life Sciences, Graduate School of Agriculture Kyoto University Kyoto Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15622

Reference50 articles.

1. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

3. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

4. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

5. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptor protein CEMIP reduces the chemosensitivity of small cell lung cancer via activation of an SRC-YAP oncogenic module;Acta Pharmacologica Sinica;2024-07-23

2. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers;Cancer Gene Therapy;2024-03-18

3. Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer;Molecular Cancer Therapeutics;2023-12-06

4. YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer;International Journal of Molecular Sciences;2023-08-06